Companies › NovoCure
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NovoTTF-200T Delivers tumor treating fields (TTFields) at 150kHz frequency to physically disrupt rapid | – | Phase 3 | Metastatic Non-small Cell Lung Cancer; Pancreatic Adenocarcinoma | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05624918 | NovoTTF-200T | Phase 2 | Pancreatic Adenocarcinoma | Oncology | Aug 2027 |
| NCT06216301 | NovoTTF-200T | Phase 3 | Metastatic Non-small Cell Lung Cancer | Oncology | Oct 2028 |
Cash and short-term investments of $463m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
SynOx Therapeutics NingBo Junyan Hongshi Biosciences Taizhou Hanzhong biomedical InSightec Summit Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.